How will the recent withdrawal of Ocaliva for the treatment of PBC impact your therapeutic and management plan for these patients?  

It was unfortunate to lose a drug that was effective for many PBC patients but the FDA approved 2 new PBC drugs last year. These are PPAR agonists (elafibranor and seladelpar) and are well-tolerated and have been effective in reducing ALP in PBC. These are second-line add-on drugs to UDCA (should be...